Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of aesculin XVII or pharmaceutically acceptable salt thereof in preparation of medicine for preventing and treating non-alcoholic fatty liver disease

A technology for fatty liver disease and escin, applied in the field of biomedicine, can solve problems such as unclear efficacy, achieve the effects of reducing lipid accumulation, improving NAFLD, and increasing ALB content

Pending Publication Date: 2022-01-04
湖州市食品药品检验研究院
View PDF4 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

There are many kinds of active ingredients in Panax notoginseng, and there are more than 20 kinds of saponins isolated from the stems and leaves of Panax notoginseng, and the efficacy of each saponin monomer is still unclear
[0005] Currently, there is no literature reporting that escin XVII can be used in the treatment of NAFLD

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of aesculin XVII or pharmaceutically acceptable salt thereof in preparation of medicine for preventing and treating non-alcoholic fatty liver disease
  • Application of aesculin XVII or pharmaceutically acceptable salt thereof in preparation of medicine for preventing and treating non-alcoholic fatty liver disease
  • Application of aesculin XVII or pharmaceutically acceptable salt thereof in preparation of medicine for preventing and treating non-alcoholic fatty liver disease

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0032] Example 1 Study on the effect of the concentration of escin XVII on the viability of HepG2 cells

[0033] 1. Experimental reagents

[0034] Aescin XVII was purchased from Chengdu Desite Biotechnology Co., Ltd. (purity ≥ 98%), HepG2 cells were purchased from American Tissue Culture Collection (ATCC, Manassas, VA, USA), penicillin and streptomycin were purchased from Sigma ( St.Louis, MO, USA), EMEM medium was purchased from Gibco, Invitrogen Corporation (NY, USA), and CCK8 kit was purchased from Beyond Biotechnology Co., Ltd. (ShangHai, China).

[0035] 2. Cell culture and cell viability assay

[0036] Experimental group: HepG2 cells were incubated with escin XVII at final concentrations of 0.1, 0.3, 1, 3, 10, and 30 μg / ml in the culture medium;

[0037] Control group: culture medium without escin XVII to incubate HepG2 cells.

[0038] The HepG2 cells were subcultured in the EMEM medium containing penicillin (final concentration of 100 U / ml), streptomycin (final conce...

Embodiment 2

[0042] Example 2 Study on the therapeutic effect of escin XVII on NAFLD

[0043] 1. Experimental reagents

[0044] FBS was purchased from Gibco, Invitrogen Corporation (NY, USA); trypsin was purchased from Gibco (Grand Island, NY, USA); penicillin and streptomycin were purchased from Sigma (St.Louis, MO, USA); EMEM medium was purchased from Gibco, Invitrogen Corporation (NY, USA); Oil Red O staining solution was purchased from Suo Laibao Company (Beijing, China); Triglyceride Assay Kit-Quantification (ab65336) was purchased from Abcam Company (Cambridge, UK); ASTActivity Assay Kit (K753 -100), ALT Activity Assay Kit (K752-100) were purchased from BioVision Company (Milpitas, CA, USA); Human Albumin ELISA Kit (SEKH-0081) was purchased from Suleibao Company (Beijing, China); Human TNF-alpha Quantikine ELISA Kit (DTA00D), Human IL-1β / IL-1F2 Quantikine ELISA Kit (DLB50) were purchased from R&D Company (Minnesota, USA).

[0045] 2. Cell culture and determination of related parame...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses application of aesculin XVII or pharmaceutically acceptable salt thereof in preparation of a medicine for preventing and treating a non-alcoholic fatty liver disease. By constructing a cell model of the non-alcoholic fatty liver disease, aesculin XVII can increase the content of ALB, reduce the level of AST, ALT, TG, TNF-alpha and IL-1 beta and reduce formation of lipid droplets in liver cells, and therefore the non-alcoholic fatty liver disease is prevented and treated.

Description

technical field [0001] The invention relates to the field of biomedicine, in particular to the application of escin XVII or a pharmaceutically acceptable salt thereof in the preparation of drugs for preventing and treating non-alcoholic fatty liver disease. Background technique [0002] Nonalcoholic fatty liver disease (NAFLD) refers to a clinicopathological syndrome characterized by excessive fat deposition in liver cells caused by alcohol or other definite liver damage factors. Studies have shown that the global prevalence of NAFLD is about 25.24%, and it has become the second most common liver disease after viral hepatitis, seriously threatening human health. The pathogenesis of NAFLD has not been fully elucidated, and the most widely accepted theory is the "two-hit theory": the first attack of the pathogenesis of NAFLD is the accumulation of triglyceride (TG) and free fatty acid (FFA) in liver cells, forming Hepatocyte steatosis, which triggers hepatocytes and liver mac...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/704A61K36/258A61K36/424A61P1/16
CPCA61K31/704A61K36/258A61K36/424A61P1/16
Inventor 诸夔妞王新财陈晓平成霄杨红霞
Owner 湖州市食品药品检验研究院
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com